Andrew Olaye

Executive Director, Market Access & Partnerships EMEA • Orchard Therapeutics

Andrew Olaye has worked in the Pharmaceutical industry and academic institutes for nearly 20 years, with the last 10 years in companies dedicated to treatment of rare diseases, during which he has contributed to the successful commercialisation of several ATMPs including Libmeldy, Strimvelis and Roctavian as well as several orphan drugs within Europe and the middle east. His current responsibilities at Orchard include coordinating the market access activities and external partnerships in Europe and Middle East